Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1947 1
1948 1
1950 1
1951 1
1954 1
1955 1
1957 3
1958 2
1959 6
1960 2
1961 1
1962 4
1963 1
1964 2
1965 4
1967 2
1970 1
1971 2
1972 2
1973 3
1974 1
1975 1
1976 3
1977 1
1978 3
1979 1
1980 1
1982 1
1987 1
1988 1
1989 2
1990 1
1991 3
1992 3
1993 2
1995 1
1996 2
1999 1
2000 3
2001 1
2004 1
2005 4
2006 2
2008 4
2009 5
2010 2
2011 3
2013 1
2014 2
2015 4
2016 5
2017 12
2018 14
2019 11
2020 9
2021 21
2022 11
2023 17
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

180 results

Results by year

Filters applied: . Clear all
Page 1
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.
Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, Campone M, Blackwell KL, André F, Winer EP, Janni W, Verma S, Conte P, Arteaga CL, Cameron DA, Petrakova K, Hart LL, Villanueva C, Chan A, Jakobsen E, Nusch A, Burdaeva O, Grischke EM, Alba E, Wist E, Marschner N, Favret AM, Yardley D, Bachelot T, Tseng LM, Blau S, Xuan F, Souami F, Miller M, Germa C, Hirawat S, O'Shaughnessy J. Hortobagyi GN, et al. Among authors: blau s. N Engl J Med. 2016 Nov 3;375(18):1738-1748. doi: 10.1056/NEJMoa1609709. Epub 2016 Oct 7. N Engl J Med. 2016. PMID: 27717303 Free article. Clinical Trial.
Phase I/II Trial of Exemestane, Ribociclib, and Everolimus in Women with HR+/HER2- Advanced Breast Cancer after Progression on CDK4/6 Inhibitors (TRINITI-1).
Bardia A, Hurvitz SA, DeMichele A, Clark AS, Zelnak A, Yardley DA, Karuturi M, Sanft T, Blau S, Hart L, Ma C, Rugo HS, Purkayastha D, Moulder S. Bardia A, et al. Among authors: blau s. Clin Cancer Res. 2021 Aug 1;27(15):4177-4185. doi: 10.1158/1078-0432.CCR-20-2114. Epub 2021 Mar 15. Clin Cancer Res. 2021. PMID: 33722897 Free PMC article. Clinical Trial.
Body farms.
Blau S. Blau S. Forensic Sci Med Pathol. 2017 Dec;13(4):484-486. doi: 10.1007/s12024-017-9922-1. Epub 2017 Oct 2. Forensic Sci Med Pathol. 2017. PMID: 28967034 No abstract available.
Chemical reaction networks and opportunities for machine learning.
Wen M, Spotte-Smith EWC, Blau SM, McDermott MJ, Krishnapriyan AS, Persson KA. Wen M, et al. Among authors: blau sm. Nat Comput Sci. 2023 Jan;3(1):12-24. doi: 10.1038/s43588-022-00369-z. Epub 2023 Jan 16. Nat Comput Sci. 2023. PMID: 38177958 Review.
Clinical characteristics, racial inequities, and outcomes in patients with breast cancer and COVID-19: A COVID-19 and cancer consortium (CCC19) cohort study.
Nagaraj G, Vinayak S, Khaki AR, Sun T, Kuderer NM, Aboulafia DM, Acoba JD, Awosika J, Bakouny Z, Balmaceda NB, Bao T, Bashir B, Berg S, Bilen MA, Bindal P, Blau S, Bodin BE, Borno HT, Castellano C, Choi H, Deeken J, Desai A, Edwin N, Feldman LE, Flora DB, Friese CR, Galsky MD, Gonzalez CJ, Grivas P, Gupta S, Haynam M, Heilman H, Hershman DL, Hwang C, Jani C, Jhawar SR, Joshi M, Kaklamani V, Klein EJ, Knox N, Koshkin VS, Kulkarni AA, Kwon DH, Labaki C, Lammers PE, Lathrop KI, Lewis MA, Li X, Lopes GL, Lyman GH, Makower DF, Mansoor AH, Markham MJ, Mashru SH, McKay RR, Messing I, Mico V, Nadkarni R, Namburi S, Nguyen RH, Nonato TK, O'Connor TL, Panagiotou OA, Park K, Patel JM, Patel KG, Peppercorn J, Polimera H, Puc M, Rao YJ, Razavi P, Reid SA, Riess JW, Rivera DR, Robson M, Rose SJ, Russ AD, Schapira L, Shah PK, Shanahan MK, Shapiro LC, Smits M, Stover DG, Streckfuss M, Tachiki L, Thompson MA, Tolaney SM, Weissmann LB, Wilson G, Wotman MT, Wulff-Burchfield EM, Mishra S, French B, Warner JL, Lustberg MB, Accordino MK, Shah DP; COVID-19 and Cancer Consortium. Nagaraj G, et al. Among authors: blau s. Elife. 2023 Oct 17;12:e82618. doi: 10.7554/eLife.82618. Elife. 2023. PMID: 37846664 Free PMC article.
XENERA-1: a randomised double-blind Phase II trial of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in patients with hormone receptor-positive/HER2-negative metastatic breast cancer and non-visceral disease.
Schmid P, Cortes J, Joaquim A, Jañez NM, Morales S, Díaz-Redondo T, Blau S, Neven P, Lemieux J, García-Sáenz JÁ, Hart L, Biyukov T, Baktash N, Massey D, Burris HA 3rd, Rugo HS. Schmid P, et al. Among authors: blau s. Breast Cancer Res. 2023 Jun 12;25(1):67. doi: 10.1186/s13058-023-01649-w. Breast Cancer Res. 2023. PMID: 37308971 Free PMC article. Clinical Trial.
Recording skeletal completeness: A standardised approach.
Rowbotham SK, Blau S, Hislop-Jambrich J. Rowbotham SK, et al. Among authors: blau s. Forensic Sci Int. 2017 Jun;275:117-123. doi: 10.1016/j.forsciint.2017.02.036. Epub 2017 Mar 8. Forensic Sci Int. 2017. PMID: 28343025
17q21 Variants Disturb Mucosal Host Defense in Childhood Asthma.
Jakwerth CA, Weckmann M, Illi S, Charles H, Zissler UM, Oelsner M, Guerth F, Omony J, Nemani SSP, Grychtol R, Dittrich AM, Skevaki C, Foth S, Weber S, Alejandre Alcazar MA, van Koningsbruggen-Rietschel S, Brock R, Blau S, Hansen G, Bahmer T, Rabe KF, Brinkmann F, Kopp MV, Chaker AM, Schaub B, von Mutius E, Schmidt-Weber CB; ALLIANCE Study Group as part of the German Center for Lung Research (DZL). Jakwerth CA, et al. Among authors: blau s. Am J Respir Crit Care Med. 2023 Dec 8. doi: 10.1164/rccm.202305-0934OC. Online ahead of print. Am J Respir Crit Care Med. 2023. PMID: 38064241
180 results